When CD8 cells were depleted, the efficacy of the triple therapy diminished, thus indicating the crucial contribution of the CD8+ T cells in this treatment strategy, a finding that is in line with that observed in breast cancer models [171]. The gene discussed is CD8A; the disease is breast carcinoma.